Nestle India under SEBI net, gets warning letter

Published On 2025-03-10 11:35 GMT | Update On 2025-03-10 11:35 GMT

New Delhi: FMCG major Nestle India has received administrative warning letter from the Securities and Exchange Board of India (SEBI) over alleged violation of Insider Trading norms by a senior official of the company.

"The Compliance Officer of the Company has received an administrative warning letter from the Deputy General Manager of SEBI for violation of SEBI (Prohibition of Insider Trading) Regulations, 2015 ('PIT Regulations') by a designated person of the Company," the Company said in a BSE filing.

Nestle India has not disclosed the identity of the person involved in this.

Later in a statement, Nestle India spokesperson said it will have no material impact on the company.

According to PTI, Nestle India said, "We would like to categorically assert that this information has no impact on the financial and operational capabilities of the company. The information has been provided in accordance with Regulation 30 of SEBI Listing Regulations,"

Insider trading is one of the most serious malpractices that exists in the market.

It is selling or buying securities such as equity and bonds by the insiders of a company, which includes the employees, directors, executives and promoters.

To prevent such acts and to promote fair trading in the market for the interest of common investors, Sebi has prohibited the firms from purchasing their own shares from the secondary market.

Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Nestle India under SEBI net, gets warning letter

Similar News

CDSCO Tightens RTI Appeal Timelines, Division Heads to Face Penalties for Lapses

Patna HC Denies Bail in Codeine Syrup Case: Possession Below 2.5% Still NDPS Offence

Alembic Pharma Gets USFDA Nod for Generic Paxil CR Tablets

Game-Changer for HIV: Dr Reddy's, Hetero to Sell Generic Lenacapavir at Rs 3,547 a Year

Sanofi Commits USD 625 Million to Sanofi Ventures to Boost Biotech and Digital Health Startups

Syneos Health Asked to Clarify Phase II Tacrolimus Trial Protocol by CDSCO Panel

Zydus Lifesciences Gets CDSCO Panel Nod for Bioavailability Study of Antimalarial Candidate ZY-19489

Serum Institute, Vidal Health Partner for Digital Cashless HPV Vaccination Programme